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Response criteria for pediatric high-grade glioma (pHGG) has varied both historically and across 
different cooperative groups. The Response Assessment in Neuro-Oncology (RANO) working 
group has developed response criteria for adult HGG and was not created for the unique 
challenges in pHGG. An international Response Assessment in Pediatric Neuro-Oncology 
(RAPNO) working group was established to develop response assessment criteria for pHGG. 
Current practice and literature were reviewed to identify major issues. In areas where scientific 
investigation was lacking, consensus was reached through an iterative process. 
Recommendations from RAPNO for response assessment include the use of magnetic 
resonance imaging (MRI) of both the brain and spine, assessing clinical status, and the use of 
corticosteroids or anti-angiogenic agents. Imaging standards for brain and spine are defined. 
Compared to the adult RANO, there is a higher reliance on T2/FLAIR imaging and inclusion of 
diffusion-weighted imaging. Consensus recommendations and response definitions have been 
established and, similar to other RAPNO recommendations, prospective validation in clinical 
trials is warranted.  
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Pediatric HGG RAPNO Search Strategy and Selection Criteria References for this review were 
identified through searches of PubMed with the search terms “high-grade glioma,” “pediatric,” 
“radiologic assessment, “response,” “leptomeningeal,” “pseudoprogression,” 
“immunotherapy,” “advanced imaging,” “health-related quality of life,” circulating tumor DNA,” 
“radiomics”, “MGMT methylation” and “RANO,” from 1990 until June 2019. Articles were also 
identified through searches of the authors’ own files. Only papers published in English were 
reviewed. The final reference list was generated on the basis of originality and relevance to the 


















Pediatric high-grade gliomas (pHGG) account for 8-12% of CNS tumors in children with the 
majority having a non-brainstem location.1,2 Pediatric HGGs are the leading cause of cancer-
related death in children under 19 years of age and include a variety of different World Health 
Organization (WHO) grade III and IV histologies as well as H3 K27M-mutant diffuse midline 
glioma (DMG).3,4 This report focuses on DMG and other biopsy-proven pHGG entities but 
excludes anaplastic ependymoma and diffuse intrinsic pontine glioma (DIPG) whether or not 
biopsied. Compared to non-pontine DMG, DIPG is better correlated with pontine size and 
T2/FLAIR measurements. DIPG response assessment is, therefore, the subject of a separate 
RAPNO working group. For non-pontine DMG, it is unclear how to best assess their response 
and are currently included in this consensus statement as apposed to inclusion with DIPG. In 
the future, it may become evident whether or not DMG patients should be incorporated 
separately from other pHGG for response assessment purposes. Excluding DIPG, pHGG have a 
3-year event-free survival (EFS) and overall survival (OS) of roughly 10 and 20% respectively.5 
Significant recent advances towards understanding the biology of pHGG have strongly 
influenced new clinical trial design and endpoints.6,7 However, there are no specific criteria to 
unify response assessment across studies. 
 
The Children’s Oncology Group (COG) has traditionally relied on MRI for objective response 
assessment although non-standardized clinical assessment and time from completion of 
radiation therapy are also considered when assessing progressive disease (PD). Other working 
groups such as the Pediatric Brain Tumor Consortium (PBTC), use criteria similar to COG but 
incorporate neurologic status, corticosteroid dosing, and durability of response. Several Société 
Internationale D’Oncologie Pédiatrique (SIOP) studies have defined response using radiographic 
assessment only.8,9 Recently the international multicenter study, High-grade glioma Efficacy and 
tolerability Research of Bevacizumab in Young children and adolescents (HERBY) compared the 
addition of bevacizumab to radiotherapy-temozolomide in pHGG and incorporated RANO 
assessments.10-13 Using RANO, the HERBY study required a high adjudication rate for the expert 
panel radiological read, resulted in notable differences in date of progression comparing local 
to central review, and increased read times per patient, in part, due to inconsistent lesion 
diameter measurements, highlighting the need for consensus criteria.14  
 
There are several differences between pediatric and adult HGGs with regard to tumor biology, 
tumor location, higher likelihood of leptomeningeal dissemination, and an increased frequency 
of non-enhancing tumors.15 These differences and the use of a variety of response assessments 
for pHGG across different studies have led herein to the development of standardized response 
assessment criteria from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) 
working group.16 The RAPNO pHGG subcommittee consists of pediatric and adult neuro-
oncologists, neuro-radiologists and experts in imaging informatics. This committee developed a 
consensus statement and established a unified response assessment for pHGG by first 
identifying major challenges, reviewing existing literature and current practices, and finally 
developing recommendations through an iterative process.  
 
Current Challenges with Response Assessment in pHGG 
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Lack of Imaging Standards for pHGG Clinical Trials 
Conventional MRI is the current standard for response assessment in pHGG. However, MRI time 
points and protocols may vary between institutions and clinical trials. Furthermore, some 
sequence acquisition recommendations are inconsistent across studies, and may or may not 
include advanced imaging.14 
 
For baseline scans in newly diagnosed disease, Ellingson et al. challenged the use of post-
operative MRI in adult glioblastoma clinical trials10 due to the propensity to develop 
pseudoprogression within the first 12 weeks of chemoradiotherapy. In adult glioblastoma, it is 
now recommended to use the first post chemoradiotherapy MRI as the baseline scan, as 
opposed to the first post-operative MRI10 to reduce the challenges posed by blood products, 
increased vascular permeability, imaging variation secondary to surgical complexity, and 
perisurgical steroid use. Despite this recommendation, many pediatric clinical trials still include 
the post-operative MRI as baseline imaging in the response assessment period. 
 
Measurable and Non-measurable Disease 
Response assessment in brain tumors is highly dependent on radiographic criteria, and several 
methods have been proposed for measuring extent of disease including the traditional WHO 
two-dimensional method (product of the longest diameter and its longest perpendicular 
diameter)17 as well as the recommended one-dimensional method implemented by the RECIST 
criteria (sum of the longest dimensions). However, in the last decade, in part due to the 
infiltrative nature of gliomas causing inherent challenges for linear measurements, 3D 
volumetric assessment is gaining popularity, although the best measuring technique, i.e. that 
which most correlates with outcomes, is not known. 
 
Pediatric HGGs are often diffusely infiltrative with ill-defined margins and inhomogeneous 
contrast enhancement, making tumor measurement, and hence, identification of response 
challenging. Historically, measurable disease for HGGs has been defined by the extent of 
contrast enhancement, with response assessment recommendations published by Macdonald 
in 1990 focusing entirely on enhancing lesions as surrogates of tumor burden.18 However, 
contrast enhancement serves as a marker for regions of blood-brain barrier disruption and is 
not specific for tumor16 with the differential diagnosis including infection, post-surgical 
changes, as well as radiation injury and treatment-related inflammation.13  
 
Defining non-measurable disease and determining whether this component should be 
quantitatively addressed is controversial. In the initial MacDonald criteria, the non-enhancing 
T2 and fluid-attenuated inversion recovery (FLAIR) infiltrative tumor component was not 
included as changes attributed to concomitant medications, such as steroids, could not be 
delineated from treatment-related changes.18 This is a notable limitation, as changes in non-
enhancing tumor may occur prior to changes in contrast-enhancing portions of the tumor.19-21 
In 2010, the RANO working group attempted to address these limitations by incorporating 
T2/FLAIR changes into response criteria.11 Due to inherent difficulty in accurately measuring 
non-enhancing tumor, a subjective approach was proposed, with progression defined as 
“significant” increase in T2/FLAIR changes felt to represent tumor as opposed to other non-
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neoplastic processes such as post-surgical changes, radiation injury, demyelination, ischemic 
injury, or infection.11,12 Unlike RANO, the COG and PBTC have traditionally allowed for 
quantitative two-dimensional measurement of non-enhancing tumor and incorporated this into 
their response assessment.  
 
The best way to evaluate non-enhancing tumor for response assessment is a critical question as 
pHGGs often contain non-enhancing infiltrative components or can be entirely non-enhancing. 
Therefore the use of contrast enhancement as a surrogate for tumor burden in pHGGs often 
underestimates the overall extent of tumor and can lead to inaccurate response assessment. In 
the HERBY study, diagnostic (pre-operative) imaging showed that 32 of 98 cases had little or no 
enhancement15 while after surgery this number increased to nearly 80% of lesions 
predominately appearing as a non-enhancing infiltrative mass with increased T2/FLAIR signal.22 
This experience suggests that only a minority of newly diagnosed pHGG would be expected to 
have significant contrast-enhancing disease after primary surgery. Furthermore, contrast 
enhancement in pHGG is almost never the sole determinant used to determine progression in 
pHGG and generally is accompanied by non-enhancing tumor growth on T2/FLAIR and/or 
clinical decline.14 Given these findings, changes in non-enhancing tumor are important to 
characterize in pHGG response assessment. 
 
Spine Imaging for Leptomeningeal Dissemination Detection 
Plaque-like or nodular dissemination of tumor to the leptomeninges of the brain or spinal cord 
can occur in pHGG but is less common compared to other tumors such as medulloblastoma and 
ependymoma.23 Primary or secondary leptomeningeal dissemination rates in pHGG ranges 
between 10% -30% and impacts OS.15,22,24-26 In the HERBY trial, spinal leptomeningeal disease 
occurred in both DMG and hemispheric pHGG, although more frequently in subjects with DMG, 
and in several cases, the spine was the only involved site.15 In pHGG, there is no standard for 
obtaining initial or follow-up spine imaging and routine evaluation of spinal disease in the 
context of clinical trials is frequently not performed. Prior recommendations for response 
assessment of adult HGG per the RANO committee have not included imaging protocols for the 
spine. The known occurrence of primary and secondary leptomeningeal dissemination in pHGG 
underlines the need for clear recommendations. 
 
Imaging Changes Related to Therapy 
Pseudoresponse is a term used to describe radiographic improvement with overall decreased 
edema and/or contrast enhancement secondary to the normalization effect of anti-angiogenic 
agents on the permeability of leaky endothelium without a change in survival outcome.27 In 
these cases, there is generally no increased diffusivity as is seen in pseudoprogression. Clinical 
trials using bevacizumab in recurrent adult gliomas have demonstrated a high response rate (up 
to 63%) based on imaging with decreased contrast enhancement, without concordant 
improved survival suggesting a high rate of pseudoresponse.28-31 In addition, corticosteroids 
reduce capillary permeability, stabilize the blood-brain barrier and lessen the inflammatory 
response, which is illustrated by reduced measurable enhancing tumor as well as the 
surrounding non-enhancing components on MRI.32,33 Fortunately, unlike adult HGG, 




Pseudoprogression occurs when imaging shows a transient increase in tumor size due to 
treatment-related increase in blood-brain barrier permeability resulting in increased edema 
and/or contrast enhancement.34 Pseudoprogression occurs most frequently within the first 3 
months after chemoradiotherapy, limiting the evaluation for PD during this initial time period 
and occurs in approximately 7-12% of pHGG.13-15 Other treatment-related changes that may 
raise concern for pseudoprogression include increased enhancement such as treatment-related 
inflammation, radiation effects, seizure activity, postsurgical changes, and radiation necrosis.11 
Pseudoprogression highlights an additional challenge encountered in pHGG radiologic 
assessment. 
 
Defining refractory disease 
Many early phase clinical trials in children allow subjects to enroll with what is called refractory 
disease, but in many cases, these trials do not clearly define refractory disease nor indicate how 
potential residual active disease should be assessed.35-38 An ambiguous definition of refractory 
disease may be reasonable when the goal is to define safety and tolerability of a medication. 
However, when the trial objective is to evaluate response in the setting of stable or refractory 
disease, results may be skewed. In addition, it is not possible to radiographically distinguish 
between treatment effect and true refractory disease.  
 
Immunotherapy for pHGG 
Children with CNS tumors are increasingly enrolled in immunotherapy trials. 
Immunotherapeutic treatment modalities can incite an inflammatory response at the tumor 
site, conferring significant difficulty in deciphering inflammatory changes from true progressive 
disease using standard MRI techniques. In these situations, patients may be either prematurely 
removed from trials that are benefitting them, or alternatively, patients with truly progressive 
disease may be inappropriately continued on trial due to presumed inflammatory response, 
resulting in inaccurate response assessments. Unfortunately, clinical providers thus face 
considerably difficult clinical decision making regarding the appropriateness of therapy 
continuation for patients receiving immunotherapies.  
 
Guidelines for immunotherapeutic response assessment are currently in place through the 
adult neuro-oncology working group, immunotherapy Response Assessment in Neuro-Oncology 
(iRANO).39 These iRANO criteria do not currently address expected, and sometimes substantial, 
variations observed between different immunotherapeutic modalities such as route of 
administration, pharmacokinetics, mechanism of action, expected timing and duration of 
response, and tumor-specific variables such as the amount of target tumor antigen present.40,41 
It is recognized that even within the same therapeutic family, agents may have significant 
differences in response time or frequency of pseudoprogression.42 Currently, symptomatic 
tumor growth is classified as tumor progression by iRANO, as differentiating true progression 
from pseudoprogression is challenging.43 There is also a need to have clear indications and 
assessment criteria for the use of corticosteroids or other immunosuppressive agents, as these 
immunomodulating medications may impact immunotherapy efficacy.41 The iRANO criteria will 
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thus eventually require an update, as more data are required to fully develop and validate 
future recommendations.  
 
Repeat biopsy in the setting of determination of disease progression 
In cases where imaging is not adequate to determine response assessment, often in the setting 
of immunotherapy, novel therapeutics, or radiation therapy, tissue confirmation should be 
explored.39,44 However a consensus as to when and how to approach repeat biopsy in pHGG has 
not been clearly articulated, and no published guidelines exist on the issue. 
 
Non-radiographic assessments in pHGG 
Clinical improvement or worsening without clear imaging changes may occur in pHGG.25 The 
adult neuro-oncology community has developed the Neurologic Assessment in Neuro-Oncology 
(NANO) scale.45 However, in pediatrics, a similar tool has yet to be developed and the 
determination of clinical progression remains largely subjective.  
 
Defining Overall Response 
Overall response rate (ORR) is defined as the proportion of patients whose tumor achieved a 
partial response (PR) or complete response (CR). In treatment naïve patients, historical ORRs 
vary significantly, can range from 0 to more than 40% despite minimal advances in survival, 
likely owing to a lack of precision in measurements and inconsistent definitions.8,13,22 ORR is 
also subject to interobserver variability, confounded by irregularly shaped tumors, treatment 
effects, multifocal disease, as well as the difficulty to clearly define non-enhancing tumor 
margins. Regarding historical ORR, the PR criteria put forth by RANO of ≥ 50% decrease in the 
sum of products of perpendicular diameters from baseline may not capture all patients deriving 
true response from therapy. Therefore modification the ORR definition to better represent 
pHGG is worth exploration. In addition, measures other than ORR, such as disease control rate, 
may more accurately assess the benefit of cytostatic therapies.9,46,47  
 
RAPNO RECOMMENDATIONS 
The RAPNO pHGG committee recommends the combined use of radiographic and clinical 
evaluations in order to assess response in clinical trials. 
 
Radiologic Recommendations for Response Assessment in pHGG  
Imaging Standards for Clinical Trials  
A standardized brain MRI protocol was recently recommended by the Brain Tumor Imaging 
Standardization Steering Committee (BTISS) for endpoint assessment in clinical trials of adult 
glioblastoma48 taking into consideration acquisition feasibility ranging from small community 
centers to large academic institutions. Given that children often require anesthesia to minimize 
motion artifact, it is recommended that imaging the entire neuro-axis, when applicable, occur 
in one session to reduce anesthetic risks. Similar to RANO and BTISS, the RAPNO pHGG 
committee recommends acquiring anatomic images with sequences readily available at most 
centers to address primary study endpoints. Ideally, patients should be imaged with the same 




Diffusion-weighted imaging (DWI) is now used in nearly all centers as part of standard MRI 
protocols. It is used to identify hypercellularity, which often corresponds to grade, where lower 
apparent diffusion coefficient (ADC) values correspond to higher grade and cellularity.49-51 This 
can be helpful in pHGG to identify the hypercellular component of the tumor, which may not be 
enhancing, as well as metastatic leptomeningeal deposits (Figure 1). Diffusion is also helpful in 
the assessment of PD versus pseudoprogression where differences in diffusivity can contribute 
to distinguish hypercellular tumor (decreased ADC values) from inflammation related to 
pseudoprogression (increased ADC values) (Figure 2).52-55 Additionally, DWI plays a critical role 
in identifying progressive non-enhancing tumor in patients on anti-angiogenic therapy such as 
bevacizumab.56 When assessing diffusion, perfusion, and spectroscopy sequences in the HERBY 
trial, DWI was the most likely to directly modify tumor response assessment14 and the most 
consistently obtained technique across institutions.13 Given its potential benefit, RAPNO 
unanimously integrated DWI into pHGG response assessment. 
 
Brain Imaging 
In keeping with prior recommendations of RAPNO and RANO committees as well as the BTISS 
committee, protocol sequence recommendations are listed in Table 1. Basic standard protocol 
for tumor assessment includes the following sequences: T1-weighted images pre and post 
intravenous contrast administration, T2, T2 FLAIR and diffusion. As per prior recommendations, 
it is ideal to acquire T1-weighted images utilizing isotropic volume (3D) MR sequences for 
improved resolution and the ability to reconstruct the images in any plane as well as to perform 
volumetric assessments of tumor. The post-contrast T1 images can be acquired in 3D or 
alternatively in 2D T1-weighted images (at least 2 planes) utilizing T1 techniques such as SE, 
TSE/FSE or FLAIR if 3D techniques are not available. In either case, it is important for the 
techniques to be identical in terms of plane of acquisition and type of acquisition for the pre-
contrast and post-contrast images. Slice thickness for 2D acquisition should be no greater than 
4 mm. Of note, a specific recommendation is not provided for the type of 3D T1 acquisition 
(gradient-based versus spin-echo based technique) due to a lack of consensus regarding best 
technique. This allows for greater leeway among institutions with more limited MRI sequence 
selections that may be involved in patient recruitment for clinical trials. 
 
Spine Imaging 
Given the rates of primary and secondary leptomeningeal dissemination discussed earlier, 
standardization is necessary for full neuro-axis imaging despite the current lack of literature for 
established protocols. In order to maintain continuity with prior recommendations provided by 
RAPNO for spine imaging in medulloblastoma patients, the same specific protocol 
recommendations are made (Table 2).57  
 
Assessing Measurable and Non-Measurable Disease 
RAPNO defines measurable disease as tumor that is ≥ 1 cm or ≥ two times in both 
perpendicular diameters of the MRI axial slice thickness to decrease the partial volume effect 
plus the interslice gap. Standard 2-dimensional measurements using the largest tumor diameter 
and its largest perpendicular should be used. Most pHGGs will have only one lesion present to 
serve as the target lesion for response assessment. If, however, multiple measurable lesions are 
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present, up to 3 of the largest can be selected as “target” lesions based on their size and ability 
to be consistently measured.58,59 The sum of the products of the perpendicular diameters of 
target lesions should be used to determine response assessment. All other lesions will be 
considered non-target lesions. If a target lesion becomes non-measurable then attempts to 
continue to measure the lesion should occur unless it has disappeared.58 Determination of 
progressive disease, in this case, will only be permissible only if the lesions again enlarge to 
again meet criteria for measurable disease. 
 
RAPNO defines non-measurable disease in pHGGs as tumor too small to be accurately 
measured, < 1 cm in at least one perpendicular dimensions or < two times the MRI slice 
thickness plus the interslice gap. Leptomeningeal disease is generally non-measurable unless 
nodular areas are present. If leptomeningeal disease is present, it is assessed in a binary 
fashion, i.e. present or absent on MRI. Recognizing that what might appear as predominately 
necrotic tumor can still contain viable disease, it may be included in response assessment if its 
inclusion best represents the tumor. However, cystic lesions should be excluded from target 
lesion assessment unless the cyst is integrated within the solid component or not readily 
separable from the solid tumor component. 
 
Time points for radiologic assessments 
Newly diagnosed and Relapsed/Progressive pHGG Time points 
MRI scans for response assessment on clinical trials should occur no less than every 3 months if 
within the first year after diagnosis and considered for a slow increase of the interval 
thereafter. On the other hand, the frequency of MRI in the relapse setting should occur more 
frequently, as often as every 2 months, while on clinical trial.  
 
Post-operative brain imaging and considerations for baseline imaging  
In clinical trials assessing efficacy of concurrent chemoradiation, the post-surgical scan may be 
used as a baseline scan. There is general agreement that the initial postsurgical MRI should 
ideally take place within the first 24 hours, but within 72 hours after surgery is acceptable, to 
limit the effects of increased enhancement representing post-surgical granulation tissue which 
may mimic residual tumor.60 If there are extensive postsurgical changes that decrease the 
ability to assess residual disease and or mimic tumor infiltration, a second follow up MRI is 
recommended within 2-3 weeks after surgery. If the post-radiation scan is specified as the 
clinical trial baseline examination, it should be performed 4-8 weeks after radiation therapy is 
completed. In clinical trials for relapsed disease, the baseline MRI should be completed within 3 
weeks prior to enrollment to minimize missing rapid progression.  
 
Spine MRI 
The committee recommends spine imaging be completed concurrently with the brain MRI prior 
to clinical trial entry. If there is disease on spinal imaging prior to clinical trial entry then spine 
MRI should be followed at the same time points as brain MRI. If there is no evidence of spinal 
disease at clinical trial entry, it is permissible to monitor with brain MRI alone and complete 
further spine imaging as clinically indicated. However, in cases where a CR is being considered, 




In the case of a pHGG located primarily in the spine, a brain MRI should be completed prior to 
clinical trial entry and continued at the same time points as for the primary lesion. There is not 
enough evidence about the spread of pHGG spinal primary tumors and their frequency of brain 
metastases. In addition, the burden of adding a brain MRI to a spine is small compared to the 
addition of a spine MRI for a primary lesion in the brain. Finally, if the preoperative spine MRI is 
not obtained or there is significant artifact degradation, the baseline spine MRI should ideally 
be obtained within the first 24 hours, but within 72 hours after surgery is acceptable. 
 
Clinical, Non-Imaging, Recommendations for Response Assessment in pHGG 
Refractory Disease 
Advanced imaging may be helpful to differentiate treatment effects from recurrent/residual 
tumor but no imaging modality has sufficient specificity to conclusively differentiate the two.11 
Any attempted definition of refractory disease may lead to altered outcome measures including 
a longer duration of time to progression compared to tumors that were enrolled with definitive 
disease progression. It was unanimous among the pHGG RAPNO working group that refractory 
disease, however defined, should not be utilized in response assessment. 
 
Immunotherapy for pHGG 
It is recommended that the pediatric neuro-oncology community work alongside iRANO 
counterparts in any further update of those criteria. In the meantime, the existing initial iRANO 
criteria will be used for pHGG assessments recognizing the limitations of those criteria.39 
Furthermore, biomarkers that may act as surrogates to determine inflammatory response in 
the setting of immunotherapy and/or pseudoprogression should also be explored further as 
these may become essential for clinical trials where inflammatory responses are expected.  
  
Repeat biopsy 
The pHGG RAPNO group recommends repeat biopsy when imaging is ambiguous and the 
results may determine whether to continue therapy versus a recommendation for a change in 
treatment. When considering whether or not to pursue repeat biopsy, the physician team 
should respect both the patient and parent’s preferences while accounting for clinical factors 
and surgical risks of a repeat biopsy. If repeat biopsy is completed and reveals true PD, new 
molecular information may be gained that could influence subsequent therapies.61 However, in 
many cases, there may be a lack of access to alternative clinical trials or salvage therapies. 
Therefore, in some cases, repeat biopsy may not be clinically justified.  
 
Repeat biopsy also has technical limitations resulting from tumor heterogeneity and regional or 
spatial factors, where the biopsied sample may not be adequately representative. There is also 
a lack of standard pathological criteria to differentiate from true PD from treatment-related 
changes such as pseudoprogression. Completing image-guided biopsies may not be possible in 





If pursued, a repeat biopsy should occur be performed with spatially annotated imaging 
correlates using multiple biopsies directed at the ambiguous region to minimize sampling bias. 
If both enhancing and non-enhancing regions are present then both areas should be biopsied 
when safe and feasible. Assessment of both tumor-bearing regions as well as surrounding 
inflammatory tissue and the microenvironment should all be considered to help interpret 
pathologic results. In cases where substantial tumor is resected, rather than biopsy only, the 
post-procedure MRI should serve as a new baseline. Systematic repeat biopsies within clinical 
trials may further help to distinguish PD from treatment-related changes based on 
morphologic, cellular and/or molecular features and should be done in concert with advanced 
imaging techniques so that, in the future, we may be able to accurately distinguish these 
changes without invasive procedures.  
 
Clinical Trial Endpoint Considerations in pHGG Response Assessment 
The RAPNO pHGG committee has recommended the creation of a minor response (MR) 
category which includes ≥ 25% reduction of the sum of the products of the two perpendicular 
diameters of all target lesions in addition to other radiographic and clinical parameters. This is 
different than the RAPNO DIPG response criteria which will not have a MR category, but 
instead, accept a 25% reduction for PR criteria based upon previously published data which is 
lacking for pHGG.62 The addition of a MR category for pHGG allows better comparison of PR 
criteria to historical cohorts, new correlations with clinical trial endpoints, and expansion of the 
definition for ORR.  
 
In addition, other endpoints could be considered in the context of response assessment. In 
trials where cytostatic therapy is used or sustained disease stability is of clinical importance, the 
disease control rate (SD + MR + PR + CR) at a pre-specified number of weeks/months may be 
helpful to determine clinical benefit. Also, corticosteroid use can impact response assessment 
and have considerable side-effects, therefore their use has been recently developed into an 
endpoint for pediatric neuro-oncology patients through RANO, although requires further 
validation.63 The use of these additional endpoints should be considered on a trial to trial basis.  
 
Non-radiographic assessments in pHGG 
In pediatrics, performance scores have been shown to correlate with OS,64 and include the 
Karnofsky performance score (KPS) performance status for patients ≥ 16 years of age or the 
Lansky performance score (LPS) for patients < 16 years of age. In addition, the Eastern 
Cooperative Oncology Group (ECOG) performance status may be used. Using performance 
score as a surrogate for clinical status, or neurologic deterioration unrelated to a comorbid 
condition, in pHGG response assessment is the current RAPNO recommendation until validated 
neurologic assessment tools are available for pediatric patients with brain tumors. When using 
performance score assessment tools, it is important to account for comorbid events unrelated 
to tumor, medication usage, interrater subjectivity, and difficulty with interpretation in infants. 
 
In addition to performance score, use of medications that may impact response assessment 
such as corticosteroids and/or anti-angiogenic agents and are now considered by RAPNO in 




Cerebral spinal fluid assessment  
There is a lack of literature supporting the standard use of staging lumbar CSF making its 
recommended use for response assessment unclear. Exploration of CSF for malignant cells 
should continue to be assessed and correlated with CSF biomarkers and imaging findings to 
further refine response assessment. If CSF cytology is assessed and found to be positive, it must 
be re-assessed and found to be negative to meet criteria for complete response. 
 
RAPNO Recommendations for Response Assessment 
Based on the literature, existing practice, and experience, the committee has developed criteria 
for defining response or progression in patients with pHGG enrolled in clinical trials (Table 3). 
Importantly, many pHGGs have little or no enhancement but generally have well-defined 
margins that can be identified for measurement with T2/FLAIR.15 However, in some cases of 
hemispheric pHGG, defining non-enhancing tumor margins for measurement is unclear due to 
difficulty in differentiating tumor from vasogenic edema. In these cases, concurrent 
involvement of T2/FLAIR signal within gray matter structures or the presence of diffusion 
restriction supports tumor involvement over edema. Therefore assessing non-enhancing or 
minimally enhancing tumor with quantitative measurements is recommended. RAPNO 
recommends the sequence most representative of the tumor be used to determine response 
assessment whether this is T1 contrast-enhancing disease or T2/FLAIR in tumors with minimal 
or no enhancement on baseline MRI. The sequence selected for measurable disease at baseline 
should then continue to be used moving forward. For DWI, there are limitations for its use in 
quantitative measures due to susceptibility effects of post-surgical change and or hemorrhage 
in the tumor as well as differences in field strength acquisition parameters. Therefore RAPNO 
recommends, DWI as a qualitative measure for response assessment. 
 
In order to determine objective response (CR, PR or MR) or stable disease, all criteria must be 
met including those of measurable disease, DWI, new lesion assessment, clinical status, and 
anti-angiogenic and/or corticosteroid use. For PR, RAPNO recommends a ≥50% decrease of 
measurable disease in the bidirectional product of perpendicular diameters lasting at least 8 
weeks, but recognize that ≥25% reduction is a meaningful decrease and should be considered a 
MR. However, MR may be more subject to interrater variability due to the smaller changes 
needed compared to PR.  
 
If any response assessment criterion is not initially assessed, then objective response is 
considered indeterminate with the exception of DWI. If DWI is not obtained at baseline then 
determination of tumor response or progression is acceptable with the omission of that 
criterion moving forward. RAPNO has selected sequences for response assessment because of 
their widespread use and acceptance which is hoped to limit the transition time needed to 
implement these new response criteria.  
 
Determination of PD may occur when meeting any of the following criteria: ≥ 25% increase 
measurable disease, presence of a new lesion, or worsening clinical status. As DWI has not 
previously been used alone to determine PD, it must be used in conjunction with other 
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radiographic determinants. Similar to RANO, medications such as anti-angiogenic or 
corticosteroid use will not be used to determine progression in the absence of clinical 
deterioration. It is recognized that using T2/FLAIR measurement to determine PD offers 
challenges specifically with differentiating PD from vasogenic edema. The RAPNO committee 
suggests PD is more likely when increases in T2/FLAIR changes are accompanied by any or all of 
the following: 1) new or increased contrast enhancement, 2) new or enlarging area of diffusion 
restriction, 3) new/enlarging area of infiltrative changes involving gray matter structures.  
 
In order to determine response, whether CR, PR, MR, or SD all tumors must meet the criteria 
over 2-time points at least 8 weeks apart. RAPNO recommends a minimum of least 8 weeks 
between imaging time points in order to document response, instead of 4 weeks per RANO, as 
it is difficult to obtain MRI scans in a 4-week interval due to several factors including the 
frequent need for anesthesia. In times when PD is unclear a short interval repeat MRI in 4-8 
weeks with consideration of repeat biopsy may be performed and the PD be backdated to the 
initial time point where concern was noted.  
 
Clinical or neurologic deterioration is best determined by the treating physician, while 
performance score can be used an assessment tool. For the LPS or KPS a decline from 100 or 90 
to 70 or less, a decline of at least 20 from 80 or less, or a decline from any baseline to 50 or less, 
for at least 7 days, should be considered clinical deterioration unless attributable to comorbid 
events or changes in corticosteroid dose. Similarly, a decline in the ECOG performance scores 
from 0 or 1 to 2, or 2 to 3 would be considered neurologic deterioration.11  
 
The RAPNO guidelines do not have an upper age limit but were specifically designed with pHGG 
in mind. As many pediatric clinical trials include patients > 18 years old, it is recommended that 
one primary response assessment be chosen. If the clinical trial is largely represented by adult 
glioblastoma multiforme, then RANO should be primarily used. For the adolescent and young 
adult (AYA) population, it would be reasonable to compare RANO and RAPNO and their 
associations with ORR, EFS and OS. There are several differences between RAPNO and RANO 
which are demonstrated on Table 4.  
 
Due to the relatively low frequency and poor outcomes of pHGG, clinical trials are frequently 
single-arm studies that require well-defined and uniform historic control information. The 
pHGG RAPNO recommendations may make direct comparison to historical endpoints more 
challenging. Although it is hoped these response criteria will add value, in some cases, new 
benchmarks may need to be established for future comparisons. Specifically, the addition of 
MR to objective response along with PR and CR may increase the ORR compared to historical 
controls. As a result, clinical trial endpoints will need to be correlated and validated with these 
new RAPNO criteria. 
 
Future Considerations for Response Assessment in pHGG 
The Role of Advanced Imaging 
Advanced MR imaging techniques can complement conventional MRI sequences and provide 
additional physiologic/functional information. Techniques including Perfusion Weighted 
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Imaging (PWI) and Magnetic Resonance Spectroscopy (MRS) can be useful in the evaluation of 
treatment-related changes such as differentiation between pseudoprogression and true PD,65 
and they have been shown to help predict a patient’s tumor grade.66,67 In pHGGs for instance, 
PWI rCBV > 1.4 has been correlated with shorter survival in those treated with Erlotinib.68  
 
Although there are advantages with the use of advanced imaging techniques, the 
standardization and implementation of these techniques across various imaging centers are 
challenging. There is additional expertise needed for interpretation, increased cost, and 
accessibility challenges across institutions that also require consideration.11,69 Overall advanced 
imaging methods with PWI and MRS remain largely experimental, although their use may be 
considered in times of ambiguous imaging with or without repeat biopsy in clinical trials. 
Further prospective data are needed before incorporation into response assessment.14 
 
Volumetric Analysis 
Volumetric analysis requires isotropic 3D sequence acquisition with post-processing software 
that is becoming more widely available and increasingly automated. In adult high-grade 
gliomas, Shah et al demonstrated that volumetric analysis was comparable to linear methods of 
tumor measurement.70 In pHGG, data is limited, but Warren et al demonstrated that detecting 
PR does not appear to be dependent on the measurement method but volumetric 
measurements may provide higher accuracy for detecting MR and  PD.71 Furthermore, a study 
looking at pediatric low-grade gliomas demonstrated a 20% discordant response assessment 
between traditional 2D measurements and volumetric analysis which may be augmented in 
pHGG where non-spherical infiltrative tumors with non-enhancing components are common.72 
Further prospective research is required in pHGG in order to implement volumetric techniques 
for clinical trials. 
 
Use of biomarkers in response assessment 
Biomarkers to assess response will be extremely valuable, and although there are currently no 
validated biomarkers to use in conjunction with radiologic response criteria in pHGG, this is an 
area of growing interest.  
 
Unlike adult HGGs, MGMT methylation status has not been shown to have a consistent impact 
on EFS or OS, nor is it associated with pseudoprogression.6,73,74 However, in pHGG, MGMT 
promoter methylation status frequently correlates with H3.3 G34 and IDH1 mutations while it is 
uncommon in tumors with H3.3/H3.1 K27 mutations which are associated with worse 
outcomes.6,75 Therefore H3 K27M status is of more prognostic significance than MGMT 
promoter methylation status and is now being increasingly stratified in the settings of clinical 
trials.  
 
The ability to assess circulating tumor DNA (ctDNA) in plasma and cerebrospinal fluid (CSF) for 
pHGGs has been demonstrated for several important mutations including H3F3A, TP53, ATRX 
and IDH1 among others.61,76-78 In addition, ctDNA may be useful in assessing disease response in 




The fields of radiomics and radiogenomics are growing quickly and may aid in future response 
assessment criteria.80 However, few studies currently exist in pHGGs.81 Radiomics offers 
promise, but significant challenges remain including reliance on multiple data sources, 
variations in imaging protocols, field strengths, settings in image-reconstruction/preprocessing 
algorithm, MRI vendors, and genetic profiling techniques. Radiomic data needs to be 
standardized and harmonized, followed by validation in order for its benefits to be incorporated 
into the clinical setting and response assessment.  
 
Health-related quality of life 
Health-related quality of life (HRQoL) is an important clinical outcome assessment but its use in 
pHGG is limited due to sparse long term data, missing time points, and confounded by steroid 
use and comorbid conditions. In pediatric neuro-oncology, the patient-reported outcomes 
measurement information system (PROMIS) and PedsQL are the two most commonly used 
HRQoL measures.82,83 Further integration of HRQoL and patient-reported outcome measures 
into pediatric neuro-oncology response may offer guidance into non-radiographic response 
assessment and further investigation is planned to be undertaken separately through RAPNO.  
 
Conclusion 
Pediatric HGGs are a unique group of tumors with a poor prognosis that require a unifying 
response assessment. The variation of response assessment criteria used across historical trials 
and the inclusion of refractory tumors in relapse trials further supports the need for 
standardized response criteria. These recommendations represent an initial effort to uniformly 
assess response and future advancements should be incorporated as appropriate. We 
recognize the lack of current validation of these guidelines, and as such, consideration for 
retrospective assessment against well-defined cohorts should be considered in addition to 
prospective assessment to evaluate feasibility and corroboration with patient outcomes. 
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